Clay Siegall is a brilliant leader and innovator in the field of biotechnology.
He began his education with a Bachelor’s of Science in Zoology from the esteemed University of Maryland and continued his education at world-renowned George Washington University where he received a Ph.D. in Genetics.
He then applied his passion and knowledge at the National Cancer Institute, National Institute of Health, and later the Bristol-Myers Squibb Pharmaceutical Research Institute. Then, in 1998 he co-founded Seattle Genetics, where Dr. Siegall currently holds the position of President, Chief Executive Officer, and Chairman of the Board. His commitment to science and innovation, in combination with business savvy, has led Dr. Siegall to his great accomplishments thus far.
On social media, such as Facebook, Dr. Siegall is portrayed as not only a brilliant scientist and innovator in the field of pharmaceuticals and cancer treatment, but also has smart business man, creative entrepreneur, passion follower, and friendly educator. There are numerous posts about his accomplishments and advances in the field of biotechnology and drugs, but also about how he realized and pursued his passion. He is approachable and down to earth, and it is clear he wants to work for people and help them.
It is clear that he is a leader of his company and someone many respected scientists admire. Seattle Genetics is devoted to creating and advancing cancer treatments and therapies. There are widespread use of harmful and evasive cancer treatments that are expensive and inconvenient, and Seattle Genetics strives to create a gene therapy that is less hindering on a patient’s life. This is the goal that led to antibody-drug conjugates (ADCs). ADCs target the cells in the body that are cancerous and harmful, and kill those cells directly, without harming the cells that are healthy. This method is hoped to greatly decrease the unfortunate side effects of other treatment therapies and be a more effective solution long term as well. Dr. Siegall was a key player in ensuring that Seattle Genetics got their patent on their first class of ADCs, ADCENTRIS.
Dr. Siegall continues to excel in the biotechnology industry.